AP1M1

Across TCGA pan-cancer cohorts, AP1M1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated AP1M1 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher AP1M1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AP1M1 expression acts as an unfavorable survival marker.

KICH and PRAD are the cancer types where AP1M1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

AP1M1–KICH (DFS)

Open the KICH breakdown →